10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2009 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2009 10-K (Filed: Mar 1, 2010) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 13,024,200 | 7,932,300 | 3,396,800 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Gain related to Merck/Schering-Plough partnership | (7,529,600) | 0 | 0 |
| Gain on disposition of interest in Merial Limited | (3,162,500) | 0 | 0 |
| Gain on distribution from AstraZeneca LP | 0 | (2,222,700) | 0 |
| Equity income from affiliates | (2,235,000) | (2,560,600) | (2,976,500) |
| Dividends and distributions from equity affiliates | 1,724,300 | 4,289,600 | 2,485,600 |
| U.S. Vioxx Settlement Agreement charge | 0 | 0 | 4,850,000 |
| Depreciation and amortization | 2,576,000 | 1,631,200 | 1,988,200 |
| Deferred income taxes | 1,820,200 | 530,100 | (1,781,900) |
| Share-based compensation | 415,500 | 348,000 | 330,200 |
| In-process research and development | 0 | 0 | 325,100 |
| Taxes paid for Internal Revenue Service settlement | 0 | 0 | (2,788,100) |
| Other | (534,200) | 607,800 | (186,100) |
| Net changes in assets and liabilities: | |||
| Accounts receivable | 165,200 | (889,400) | (290,700) |
| Inventories | 1,211,300 | (452,100) | (40,700) |
| Trade accounts payable | (45,200) | 0 | 117,700 |
| Accrued and other current liabilities | (4,003,500) | (1,710,900) | 451,100 |
| Income taxes payable | (364,800) | (465,300) | 987,200 |
| Noncurrent liabilities | 231,300 | (108,000) | 26,200 |
| Other | 98,800 | (358,300) | 105,100 |
| Net Cash Provided by Operating Activities | 3,392,000 | 6,571,700 | 6,999,200 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,460,600) | (1,298,300) | (1,011,000) |
| Purchases of securities and other investments | (3,070,800) | (11,967,300) | (10,132,700) |
| Proceeds from sales of securities and other investments | 10,941,900 | 11,065,800 | 10,860,200 |
| Proceeds from sale of interest in Merial Limited | 4,000,000 | 0 | 0 |
| Schering-Plough merger, net of cash acquired | (12,842,600) | 0 | 0 |
| Acquisitions of businesses, net of cash acquired | (130,000) | 0 | (1,135,900) |
| Distribution from AstraZeneca LP | 0 | 1,899,300 | 0 |
| Increase in restricted assets | 5,547,600 | (1,629,700) | (1,401,100) |
| Other | 170,500 | 95,800 | 10,500 |
| Net Cash Provided by (Used by) Investing Activities | 3,156,000 | (1,834,400) | (2,810,000) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | (2,422,000) | 1,859,900 | 11,400 |
| Proceeds from issuance of debt | 4,228,000 | 0 | 0 |
| Payments on debt | (25,300) | (1,392,000) | (1,195,300) |
| Purchases of treasury stock | 0 | (2,725,000) | (1,429,700) |
| Dividends paid to stockholders | (3,215,000) | (3,278,500) | (3,307,300) |
| Other dividends paid | (264,100) | (121,800) | (120,800) |
| Proceeds from exercise of stock options | 186,400 | 102,300 | 898,600 |
| Other | (126,300) | 32,600 | 277,000 |
| Net Cash Used by Financing Activities | (1,638,300) | (5,522,500) | (4,866,100) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 33,400 | (182,600) | 98,300 |
| Net Increase (Decrease) in Cash and Cash Equivalents | 4,943,100 | (967,800) | (578,600) |
| Cash and Cash Equivalents at Beginning of Year | 4,368,300 | 5,336,100 | |
| Cash and Cash Equivalents at End of Year | 9,311,400 | 4,368,300 | 5,336,100 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |